Search research articles
Contact Us
Filters
Showing results (111-120 of 127) with videos related to
Page
of 13
Sort By:
Translational Neurodegeneration
|
March 4, 2024
LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression
Noah Lubben, Julia K Brynildsen, Connor M Webb, et al.
Cell Reports
|
May 7, 2020
The Parkinson's Disease Protein LRRK2 Interacts with the GARP Complex to Promote Retrograde Transport to the trans-Golgi Network
Alexandra Beilina, Luis Bonet-Ponce, Ravindran Kumaran, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 27, 2015
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
Matthew J Fell, Christian Mirescu, Kallol Basu, et al.
ACS Medicinal Chemistry Letters
|
May 14, 2025
The Discovery of Bridged Benzoazepine Amides as Selective Allosteric Modulators of RIPK1
Joanna L Chen, Joey L Methot, Matthew J Mitcheltree, et al.
Neuropharmacology
|
July 8, 2008
Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas
Kenneth W Perry, Julie F Falcone, Matthew J Fell, et al.
Journal of Medicinal Chemistry
|
April 27, 2026
Correction to "Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease"
Elsie C Yu, Hua Zhou, Xin Yan, et al.
Journal of Medicinal Chemistry
|
March 30, 2026
Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease
Elsie C Yu, Hua Zhou, Xin Yan, et al.
Journal of Medicinal Chemistry
|
October 20, 2023
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's Disease
Solomon D Kattar, Anmol Gulati, Kaila A Margrey, et al.
RSC Medicinal Chemistry
|
August 6, 2021
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors
Anmol Gulati, Charles S Yeung, Blair Lapointe, et al.
Animal Biotelemetry
|
December 13, 2021
How often should dead-reckoned animal movement paths be corrected for drift?
Richard M Gunner, Mark D Holton, David M Scantlebury, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 127) with videos related to
Sort By:
Page
of 13
Translational Neurodegeneration
|
March 4, 2024
LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression
Noah Lubben, Julia K Brynildsen, Connor M Webb, et al.
Cell Reports
|
May 7, 2020
The Parkinson's Disease Protein LRRK2 Interacts with the GARP Complex to Promote Retrograde Transport to the trans-Golgi Network
Alexandra Beilina, Luis Bonet-Ponce, Ravindran Kumaran, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 27, 2015
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
Matthew J Fell, Christian Mirescu, Kallol Basu, et al.
ACS Medicinal Chemistry Letters
|
May 14, 2025
The Discovery of Bridged Benzoazepine Amides as Selective Allosteric Modulators of RIPK1
Joanna L Chen, Joey L Methot, Matthew J Mitcheltree, et al.
Neuropharmacology
|
July 8, 2008
Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas
Kenneth W Perry, Julie F Falcone, Matthew J Fell, et al.
Journal of Medicinal Chemistry
|
April 27, 2026
Correction to "Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease"
Elsie C Yu, Hua Zhou, Xin Yan, et al.
Journal of Medicinal Chemistry
|
March 30, 2026
Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease
Elsie C Yu, Hua Zhou, Xin Yan, et al.
Journal of Medicinal Chemistry
|
October 20, 2023
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's Disease
Solomon D Kattar, Anmol Gulati, Kaila A Margrey, et al.
RSC Medicinal Chemistry
|
August 6, 2021
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors
Anmol Gulati, Charles S Yeung, Blair Lapointe, et al.
Animal Biotelemetry
|
December 13, 2021
How often should dead-reckoned animal movement paths be corrected for drift?
Richard M Gunner, Mark D Holton, David M Scantlebury, et al.
Page
of 13